Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer

Gynecologic Oncology

Volumn 101, Issue 3, 2006, Pages 495-498

  Minagawa, Yukihisa ^a   Kigawa, Junzo ^b   Kanamori, Yasunobu ^b   Itamochi, Hiroaki ^b   Terakawa, Naoki ^b   Okada, Makoto ^c   Kitada, Fuminori ^d  

^a TOTTORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c YAMAGUCHI RED CROSS HOSPITAL   (Japan)

^d Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

Author keywords

Carboplatin; Ovarian cancer chemotherapy docetaxel cisplatin

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; FEMALE; HEADACHE; HUMAN; LEUKOPENIA; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSORY NEUROPATHY; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; TAXOIDS;

EID: 33646560903     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.11.020     Document Type: Article

References (23)

1. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J Med. 334 (1996) 1-6
2. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92 (2000) 699-708
3. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 18 (2000) 106-115
4. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 21 (2003) 3194-3200
5. du Bois A., Luck H.J., Meier W., Adams H.P., Mobus V., Costa S., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 95 (2003) 1320-1329
6. Neijt J.P., Engelholm S.A., Tuxen M.K., Sorensen P.G., Hansen M., Sessa C., et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18 (2000) 3084-3092
7. Cortes J.E., and Pazdur R. Docetaxel. J. Clin. Oncol. 13 (1995) 2643-2655
8. Kaye S.B. Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer. Semin. Oncol. 22 (1995) 30-33
9. Kaye S.B., Piccart M., Aapro M., Francis P., and Kavanagh J. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer-An updated overview. Eur. J. Cancer 33 (1997) 2167-2170
10. Rose P.G., Blessing J.A., Ball H.G., Hoffman J., Warshal D., DeGreest K., et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 88 (2003) 130-135
11. Sato S., Kigawa J., Kanamori Y., Itamochi H., Oishi T., Shimada M., et al. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells. Cancer Chemother. Pharmacol. 53 (2004) 247-252
12. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 (2004) 1682-1691
13. Go R.S., and Adjei A.A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. 17 (1999) 409-422
14. Lokich J. What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin?. Cancer Invest. 19 (2001) 756-760
15. Vasey P.A., Paul J., Birt A., Junor E.J., Reed N.S., Symonds R.P., et al. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trial Group. J. Clin. Oncol. 17 (1999) 2069-2080
16. Carvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7 (1989) 1748-1756
17. Vasey P.A., Atkinson R., Coleman R., Crawford M., Cruickshank M., Eggleton P., et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br. J. Cancer 84 (2001) 170-178
18. Markman M., Kennedy A., Webster K., Peterson G., Kulp B., and Belinson J. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J. Clin. Oncol. 19 (2001) 1901-1905
19. 2 by 3-hour infusion. Br J. Cancer 77 (1998) 1686-1688
20. New P.Z., Jackson C.E., Rinaldi D., Burris H., and Barohn R.J. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 46 (1996) 108-111
21. Kavanagh J.J., Kudelka A.P., de Leon C.G., Tresukosol D., Hord M., Finnegan M.B., et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin. Cancer Res. 2 (1996) 837-842
22. Katsumata N., Tsunematsu R., Tanaka K., Terashima Y., Ogita S., Hoshiai H., et al. A phase II trial of docetaxel in platinum pre-treated patients with advanced ovarian cancer: a Japanese cooperative study. Ann. Oncol. 11 (2000) 1531-1536
23. Aoki Y., Sato T., Tsuneki I., Watanabe M., Kase H., Fujita K., et al. Docetacel in combination with carboplatin for chemo-native patients with epithelial ovarian cancer. Int. J. Gynecol. Cancer 12 (2002) 704-709